|
Sign In to gain access to subscriptions and/or personal tools.
|
Angiotensin II receptor blockade and type 2 diabetic nephropathy
Rudy W Bilous
Audrey Collins Teaching Unit, Education Centre, The James Cook University Hospital, Marton Road, Middlesbrough, TS4 3BW, UK, r.w.bilous{at}ncl.ac.uk
ACE inhibitors have been shown to reduce albuminuria and slow the progression of nephropathy in type 1 diabetes. There are fewer data in type 2 patients.
Three large studies: IRbesartan in patients with type 2 diabetes and MicroAlbuminuria Study (IRMA2), Irbesartan Diabetic Nephropathy Trial (IDNT) and Reduction in End points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL), of the angiotensin II receptor blockers (ARBs) irbesartan and losartan in microalbuminuric (IRMA2) and nephropathic (IDNT and RENAAL) patients have recently been published. They compared ARBs to conventional treatment, and one used amlodipine as a comparator (IDNT).
IRMA2 showed that irbesartan reduced albuminuria in a dose-dependent fashion, achieving a magnitude of response similar to that seen in type 1 diabetic patients. The adjusted hazard ratio for progressing to nephropathy was 0.32 for patients treated with irbesartan 300 mg.
IDNT and RENAAL showed that irbesartan 300 mg or losartan 100 mg reduced by 16—19% the numbers of patients reaching a combined end point of doubling of baseline serum creatinine, end-stage renal failure, or all-cause mortality. This effect was not seen in amlodipine treated patients, implying a specific benefit of ARBs.
ARBs should be considered as first line therapy in both early and established type 2 diabetic nephropathy.
Key Words: angiotensin II • angiotensin receptor antagonists • diabetic nephropathy.
References
- Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:312-9.[Medline]
[Order article via Infotrieve]
- The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370-9.[Abstract/Free Full Text]
- Ritz E., Orth SR Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.[Free Full Text]
- Israili ZH, Hall WD Cough and angioneurotic edema with ACE inhibition therapy. Ann Int Med 1992;117:234-42.[Abstract/Free Full Text]
- Geiger H. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their reno-protective effect? Nephrol Dial Transplant 1997;12:640-2.[Free Full Text]
- Burns KD Angiotensin II and its receptors in the diabetic kidney. Am J Kid Dis 2000;36:449-67.[Web of Science][Medline]
[Order article via Infotrieve]
- Parving H-H., Lehnert H., Brochner-Mortensen J. et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
- Lewis EJ, Hunsicker LG, Clarke WR et al. Reno-protective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
- Brenner B., Cooper ME, de Zeeuw D. et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
- Hansen HP, Nielsen FS, Rossing P. et al. Kidney function after withdrawal of long-term anti-hypertensive treatment in diabetic nephropathy. Kidney Int 1997;52(S63):S49-53.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Heart Outcomes Prevention Evaluation (HOPE) Study Investigations. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Sub-Study. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-62.[Abstract/Free Full Text]
- Staesson JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Opie LH Reno-protection by angiotensin-receptor blockers and ACE inhibitors in hypertension. Lancet 2001;358:1829-31.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-08.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 2,
101-105 (2002)
DOI: 10.1177/14746514020020020701
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
H.-M. Jin and Y. Pan
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy
Nephrol. Dial. Transplant.,
July 1, 2007;
22(7):
1943 - 1949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Brady
Lust for LIFE: losartan and type 2 diabetes: Cardiovascular morbidity and mortality in patients with diabetes in the LIFE study
The British Journal of Diabetes & Vascular Disease,
January 1, 2003;
3(1):
45 - 46.
[PDF]
|
|
|
|
|
|
|
P. Andrews
NICE guidelines: renal disease -- prevention and early management
The British Journal of Diabetes & Vascular Disease,
July 1, 2002;
2(4):
309 - 310.
[PDF]
|
|
|
|
|
